This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schiavetti, F. Articles by Coulie, P. G. Search for Related Content PubMed PubMed Citation Articles by Schiavetti, F. Articles by Coulie, P. G.

A Human Endogenous Retroviral Sequence Encoding an Antigen Recognized on Melanoma by Cytolytic T Lymphocytes¹

Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Université de Louvain, B-1200 Brussels [F. S., J. T., T. B., P. G. C.], and Ludwig Institute for Cancer Research, Brussels Branch, B-1200 Brussels [D.C., T.B.], Belgium

We have identified a gene encoding an antigen recognized by cytolytic T lymphocytes on the autologous tumor cells of a melanoma patient, AVL3. The gene shows homologies with members of the HERV-K family of human endogenous retroviruses, and it was provisionally named HERV-K-MEL. It contains many mutations that disrupt the open reading frames coding for all of the viral proteins. The HERV-K-MEL gene is not expressed in normal tissues with the exception of testis and some skin samples. It is expressed in most samples of cutaneous and ocular melanoma. It is also expressed in a majority of naevi and in a minority of carcinomas and sarcomas. The antigenic peptide, presented by HLA-A2 molecules, is encoded by a very short open reading frame present in the env region of a spliced HERV-K-MEL transcript. Anti-HERV.A2 CTLp could not be detected in the blood of three individuals without cancer but were present at a frequency of 3 x 10^-5 among blood CD8 T cells in patient AVL3 and 6 x 10^-7 in another HLA-A2 melanoma patient whose tumor expressed HERV-K-MEL. Anti-HERV.A2 CTL clones derived from each patient lysed melanoma cells. Analysis of T-cell receptor ß chain sequences indicated that the anti-HERV.A2 CTL population was oligoclonal in patient AVL3 and probably monoclonal in the other patient. These results suggest that HERV-K-MEL is a source of antigens that are targeted by CTLs in melanoma patients and could therefore be used for vaccination.

This article has been cited by other articles:

				F. Wang-Johanning, L. Radvanyi, K. Rycaj, J. B. Plummer, P. Yan, K. J. Sastry, C. J. Piyathilake, K. K. Hunt, and G. L. Johanning Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients Cancer Res., July 15, 2008; 68(14): 5869 - 5877. [Abstract] [Full Text] [PDF]

				C. Voisset, R. A. Weiss, and D. J. Griffiths Human RNA "Rumor" Viruses: the Search for Novel Human Retroviruses in Chronic Disease Microbiol. Mol. Biol. Rev., March 1, 2008; 72(1): 157 - 196. [Abstract] [Full Text] [PDF]

				K. Buscher, U. Trefzer, M. Hofmann, W. Sterry, R. Kurth, and J. Denner Expression of Human Endogenous Retrovirus K in Melanomas and Melanoma Cell Lines Cancer Res., May 15, 2005; 65(10): 4172 - 4180. [Abstract] [Full Text] [PDF]

				M. Mangeney, J. Pothlichet, M. Renard, B. Ducos, and T. Heidmann Endogenous Retrovirus Expression Is Required for Murine Melanoma Tumor Growth In vivo Cancer Res., April 1, 2005; 65(7): 2588 - 2591. [Abstract] [Full Text] [PDF]

				J. M Grange, B. Krone, and K. Kolmel Human endogenous retroviruses in health and disease J R Soc Med, March 1, 2005; 98(3): 134 - 134. [Full Text] [PDF]

				N. Bannert and R. Kurth Retroelements and the human genome: New perspectives on an old relation PNAS, October 5, 2004; 101(suppl_2): 14572 - 14579. [Abstract] [Full Text] [PDF]

				T. Muster, A. Waltenberger, A. Grassauer, S. Hirschl, P. Caucig, I. Romirer, D. Fodinger, H. Seppele, O. Schanab, C. Magin-Lachmann, et al. An Endogenous Retrovirus Derived from Human Melanoma Cells Cancer Res., December 15, 2003; 63(24): 8735 - 8741. [Abstract] [Full Text] [PDF]

				V. Bronte, S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, C. De Santo, B. Macino, O. Marin, and P. Zanovello Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase J. Immunol., December 15, 2003; 171(12): 6396 - 6405. [Abstract] [Full Text] [PDF]

				A. Rosato, S. D. Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P.-L. Lollini, C. De Giovanni, et al. The Cytotoxic T-Lymphocyte Response against a Poorly Immunogenic Mammary Adenocarcinoma Is Focused on a Single Immunodominant Class I Epitope Derived from the gp70 Env Product of an Endogenous Retrovirus Cancer Res., May 1, 2003; 63(9): 2158 - 2163. [Abstract] [Full Text] [PDF]